Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 17, 2009 Rich Smith	This Just In: Upgrades and Downgrades Big Pharma stocks get a thumbs up from UBS.
The Motley Fool December 12, 2008 Rich Smith	This Just In: Upgrades and Downgrades Soleil Securities hands out "buy" ratings to Sepracor, Cephalon, Endo Pharm, and Pfizer.
The Motley Fool October 21, 2008 Brian Orelli	The World Is Saving Pfizer The pharma company experienced a double-digit decrease in U.S. sales in the third quarter. Ouch.
The Motley Fool November 14, 2008 Brian Orelli	Pfizer Takes the Plunge Into Stem-Cell Research The world's largest drugmaker by market cap announced today that it's forming a unit to focus on stem cells.
The Motley Fool December 18, 2008 Brian Orelli	Best Stock for 2009: Pfizer Pfizer's languishing stock price has made the company so much more attractive; it could see a breakout in 2009.
The Motley Fool December 16, 2008 Brian Orelli	Pfizer Keeps the Change For the first time in decades, investors won't get a dividend increase.
The Motley Fool July 8, 2009 Rich Smith	This Just In: Upgrades and Downgrades Banc of America shouts: "Chips ahoy!" on semiconductors.
The Motley Fool June 30, 2010 Rich Smith	This Just In: Upgrades and Downgrades Major Wall Street investment house Soleil Securities downgraded Eli Lilly shares to "sell."
The Motley Fool December 22, 2009 Brian Orelli	Pfizer Swings for the Fences A long shot, but at least it's cheap. Pfizer seems to have taken a particular liking to stem cells, having established a unit to study them last year
The Motley Fool October 20, 2008 Brian Orelli	Foolish Forecast: Will Pfizer Flounder Through Another Quarter? Pharmaceutical giant Pfizer releases earnings tomorrow morning. Let's take a look at what the numbers might say and, more importantly, what management might be able to say to get this stock out of its drug-induced coma.
The Motley Fool January 26, 2009 Brian Orelli	Deja Vu All Over Again There's hardly anything to like about Pfizer's deal to buy Wyeth. This is what got Pfizer into its problem in the first place.
The Motley Fool August 17, 2011 Ilan Moscovitz	Pfizer Is Cheaper Than You Think Let's examine Pfizer alongside some of its peers for additional context.
The Motley Fool March 26, 2009 Brian Orelli	Big Pharma's R&D Model Is Broken Bigger isn't always better.
The Motley Fool March 18, 2009 Brian Orelli	Merck Pummels Pfizer One of these acquisitions is not like the other.
The Motley Fool April 20, 2007 Ryan Fuhrmann	Discerning Pfizer's Pfuture The company is undergoing a transformation, but that doesn't mean it isn't worth a look from investors.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull The drug giant has ample firepower. The current company valuation largely ignores Pfizer's upside potential past 2008.
The Motley Fool June 11, 2008 Brian Lawler	Dueling Fools: Pfizer Bear Is Pfizer ready for a comeback? The bearish opinion is that shares may be down, but the bleeding still isn't over.
The Motley Fool January 20, 2012 Dan Caplinger	Can Geron Recover in 2012? Let's look at this year's prospects for this company.
The Motley Fool February 2, 2011 Brian Orelli	Pfizer's Newest Acquisition Target The pharma giant decided to cut potential acquisitions from its revenue guidance and instead spend the money on share buybacks.
The Motley Fool September 30, 2010 Brian Orelli	Chief Justice Roberts Sold Pfizer. Should You? Maybe, but not for the same reason.
The Motley Fool October 19, 2009 Rich Smith	This Just In: Upgrades and Downgrades Merriman Curhan Ford thinks Geron could as much as double off today's price, primarily in response to successful data on GRN163L, a treatment that targets cancer agent telomerase.
The Motley Fool October 11, 2004 Roger Nusbaum	Pfizer: Prognosis Critical This American icon seems destined to lag for the forseeable future.
The Motley Fool January 14, 2008 Brian Lawler	Worst Stock for 2008: Pfizer This analyst thinks that Pfizer is a good company, but a bad stock for 2008.
The Motley Fool April 5, 2005 Stephen D. Simpson	Pfizer Pfaces Its Pfuture Analysts and investors seem happy with Pfizer's long-term strategy. Should they be?
The Motley Fool August 30, 2010 Ilan Moscovitz	Pfizer: Dividend Dynamo or Disaster? The stability and growth of Pfizer's dividend will depend on its ability to continue to develop and grow its pipeline of drugs and successfully integrate Wyeth.
The Motley Fool December 13, 2011 Brian Orelli	Dividend? Buyback? Here's How to Get Both. But will there be enough to replenish the pipeline?
The Motley Fool August 29, 2008 Brian Orelli	Can Health-Care Dividends Hold Up? As many health-care companies' share prices drop, their dividend yields have become strikingly attractive. The big question, though, is whether these dividends can hold up.
The Motley Fool November 3, 2009 Rich Smith	This Just In: Upgrades and Downgrades Needham suspends clinical trial of buying Geron.
The Motley Fool October 30, 2009 Brian Orelli	World's Scariest Stocks: Pfizer For Pfizer, the big, scary unknown comes from whether it can integrate its recent acquisition of Wyeth.
The Motley Fool March 9, 2009 Brian Orelli	Merck-Schering Trumps Pfizer-Wyeth The new Merck deal looks a lot better than a combined Pfizer plus Wyeth.
The Motley Fool October 20, 2006 Brian Lawler	Pfizer Keeps Fighting If Pfizer's management can succeed on its cost-savings initiatives and maintain the high single digits of earnings-per-share growth that it expects in 2007-2008, then Pfizer may make a good investment for those willing to wait for the company's new drugs to bring back higher growth.
The Motley Fool January 28, 2010 Brian Orelli	Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds.
The Motley Fool June 30, 2011 Brian Orelli	Biotech Winners of a Repatriation Holiday Biotechs and dividend players will come out ahead.
The Motley Fool April 28, 2009 Brian Orelli	The Costs of Being Pfizer With Pfizer having announced its intention to buy Wyeth this quarter, investors may have worried that the negotiating and pre-acquisition planning caused management to be distracted, but that doesn't seem to be the case.
The Motley Fool November 30, 2011 Brian Orelli	3 Things More Important to Pfizer Than Losing Lipitor It's not like we didn't see it coming.
The Motley Fool June 8, 2011 Brian Orelli	Blockbuster Drug-Like Profits, No FDA Required Pfizer keeps the cuts coming.
The Motley Fool September 3, 2010 Brian Orelli	Why You Just Got Hammered Celldex's decline is due to potential reasons Pfizer would send back a drug it's been working on with Celldex for over two years
The Motley Fool August 26, 2010 Jordan DiPietro	Pfizer's Dividends May Not Last Forever Pfizer, which operates in the pharmaceuticals industry, currently pays a dividend of 4.5%. But what's more important than the dividend itself is Pfizer's ability to keep that that cash rolling.
The Motley Fool March 23, 2011 Todd Wenning	Dividend Report Card: Pfizer Investors considering Pfizer as a dividend play should decide if the combination of 4% current yield and low- to mid-single-digit dividend growth potential is a better deal than other pharmaceutical shares are offering.
The Motley Fool February 3, 2010 Brian Orelli	Wyeth Can't Save Pfizer Not much earnings growth, but the price is right.
The Motley Fool November 15, 2011 Brian Orelli	When Giving Up Is a Good Move in Biotech Geron calls it quits with stem cells.
The Motley Fool October 1, 2008 Brian Orelli	Is Pfizer the Mystery Bidder? A few signals that Pfizer might be the one bidding on ImClone.
The Motley Fool January 12, 2012 Brian Orelli	What to Look For From Pfizer in 2012 Leaner? Yes. Meaner? We'll see.
The Motley Fool February 29, 2008 Brian Orelli	2007 Pharma Roundup How did big pharma do in 2007? With the drug sector earnings season winding down, now seems like a good time to take a look at how they fared and, more importantly, where they're headed.
The Motley Fool June 1, 2007 Brian Lawler	The Generic Cracks Open for Pfizer Pfizer loses a patent case over its top compound. The larger takeaway from the Lipitor legal saga is that investors always need to be aware of the strength of a drug company's patents throughout the world.
The Motley Fool February 10, 2006 Brian Gorman	Pfizer in Pflux The company is working on its transition, but things still look fairly murky for investors.
The Motley Fool February 26, 2010 Brian Orelli	Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue.
The Motley Fool January 23, 2007 Ryan Fuhrmann	Pfizer Pfizzles Through 2006 The company is in a top-line pickle, but it expects things to get better. Current investors are now left standing until a rebound in growth, now targeted for 2009.
The Motley Fool March 24, 2009 Robert Steyer	Drugmakers Diversify -- Again Merck and Pfizer choose businesses they once eschewed.
The Motley Fool January 28, 2009 Brian Orelli	A Mini-Pfizer in the Making Bristol-Myers Squibb looks like its setting itself up to be the next Pfizer.